Article
Oncology
Nastazja Dagny Pilonis, Sarah Killcoyne, W. Keith Tan, Maria O'Donovan, Shalini Malhotra, Monika Tripathi, Ahmad Miremadi, Irene Debiram-Beecham, Tara Evans, Rosemary Phillips, Danielle L. Morris, Craig Vickery, Jon Harrison, Massimiliano di Pietro, Jacobo Ortiz-Fernandez-Sordo, Rehan Haidry, Abigail Kerridge, Peter D. Sasieni, Rebecca C. Fitzgerald
Summary: By combining Cytosponge, laboratory biomarkers, and clinical factors, endoscopy can be prioritized for patients with Barrett's oesophagus. Three risk groups were identified based on new biomarker analysis: high risk, moderate risk, and low risk. In real-world settings, Cytosponge results accurately identified high-risk patients needing endoscopy.
Review
Oncology
Leonardo Henry Eusebi, Andrea Telese, Chiara Castellana, Rengin Melis Engin, Benjamin Norton, Apostolis Papaefthymiou, Rocco Maurizio Zagari, Rehan Haidry
Summary: Barrett's oesophagus is a pathological condition characterized by the replacement of normal oesophageal squamous mucosa with specialised, intestinal-type metaplasia, which is strongly associated with chronic gastro-oesophageal reflux. Accurate diagnosis is crucial for managing Barrett's oesophagus to identify patients at high risk of developing neoplasia and guide appropriate endoscopic therapy.
Review
Medicine, General & Internal
Francesco Maione, Alessia Chini, Rosa Maione, Michele Manigrasso, Alessandra Marello, Gianluca Cassese, Nicola Gennarelli, Marco Milone, Giovanni Domenico De Palma
Summary: Barrett's Esophagus is a common condition associated with chronic gastroesophageal reflux disease and has a higher risk of developing esophageal adenocarcinoma. Low and high-grade dysplasia precede neoplastic transformation in this condition. The evaluation of low-grade dysplastic esophageal mucosa is still controversial, but endoscopic surveillance and minimally invasive endoscopic treatments such as endoscopic mucosal resection and radiofrequency ablation are available options. Cryotherapy ablation and argon plasma coagulation are novel endoscopic treatments with high eradication rates and fewer complications and post-procedural pain.
Review
Oncology
Yizi Wang, Bin Ma, Shize Yang, Wenya Li, Peiwen Li
Summary: Radiofrequency ablation (RFA) reduces the risk of progression from low-grade dysplasia (BE-LGD) to high-grade dysplasia (BE-HGD). RFA treatment is associated with a higher rate of complete eradication of dysplasia and intestinal metaplasia, but also a slightly higher rate of adverse events.
FRONTIERS IN ONCOLOGY
(2022)
Article
Cell Biology
Robert Odze, Nicola Frei, Amir M. Khoshiwal, Lucas C. Duits, Jacques Bergman, Matthew D. Stachler
Summary: This study aimed to evaluate whether the degree of crypt atypia in non-dysplastic Barrett's oesophagus patients correlates with progression to high-grade dysplasia/adenocarcinoma. The study showed that non-dysplastic crypts in Barrett's oesophagus are biologically abnormal, suggesting that neoplastic progression begins prior to the onset of dysplasia. The degree of crypt atypia in non-dysplastic Barrett's oesophagus patients correlates with disease progression.
Article
Gastroenterology & Hepatology
Maximilien Barret, Mathieu Pioche, Benoit Terris, Thierry Ponchon, Franck Cholet, Frank Zerbib, Edouard Chabrun, Marc Le Rhun, Emmanuel Coron, Marc Giovannini, Fabrice Caillol, Rene Laugier, Jeremie Jacques, Romain Legros, Christian Boustiere, Gabriel Rahmi, Elodie Metivier-Cesbron, Geoffroy Vanbiervliet, Paul Bauret, Jean Escourrou, Julien Branche, Lea Jilet, Hendy Abdoul, Nadira Kaddour, Sarah Leblanc, Michael Bensoussan, Frederic Prat, Stanislas Chaussade
Summary: This study found through a randomized trial that radiofrequency ablation therapy can moderately reduce the prevalence of low-grade dysplasia (LGD) in Barrett's esophagus over 3 years and decrease the risk of progression. The complication rate was highest after the first radiofrequency ablation treatment.
Article
Gastroenterology & Hepatology
Linda S. Yang, Bronte A. Holt, Richard Williams, Richard Norris, Edward Tsoi, Georgina Cameron, Paul Desmond, Andrew C. F. Taylor
Summary: This study retrospectively analyzed patients with dysplastic Barrett's esophagus and found that buried Barrett's mucosa was identified in 7% of cases, even in treatment-naive patients. The proposed endoscopic features showed a diagnostic accuracy of 79% in patients with histologically confirmed disease. These features may predict the presence of buried Barrett's mucosa, which could contain dysplasia or neoplasia.
GASTROINTESTINAL ENDOSCOPY
(2021)
Review
Oncology
Kevin Kyung Ho Choi, Santosh Sanagapalli
Summary: Barrett's esophagus is the precursor to esophageal adenocarcinoma and has a stepwise progression. The risk of progression is extremely low in non-dysplastic Barrett's, interventions are not justified. The risk of cancer progression in low-grade dysplasia is between 1%-3%, and endoscopic eradication therapy (EET) can be considered. High-grade dysplasia has a yearly progression risk of 5%-10%, and EET is similarly effective to surgery and should be routinely performed. In intramucosal cancer, the risk of nodal metastases is comparable to operative mortality rate, making EET the preferred treatment. Surgery remains the standard of care for submucosal cancer, except in select situations.
WORLD JOURNAL OF GASTROINTESTINAL ONCOLOGY
(2022)
Article
Gastroenterology & Hepatology
Mate Knabe, Torsten Beyna, Thomas Roesch, Jacques Bergman, Hendrik Manner, Andrea May, Guido Schachschal, Horst Neuhaus, Jennis Kandler, Bas Weusten, Oliver Pech, Siegbert Faiss, Mario Anders, Michael Vieth, Susanne Sehner, Raf Bisschops, Pradeep Bhandari, Christian Ell, Hanno Ehlken
Summary: This study evaluated a potential alternative treatment for neoplastic Barrett's esophagus, called hybrid argon plasma ablation. The results showed that this technique achieved the expected eradication and recurrence rates of Barrett's intestinal metaplasia and neoplasia within 2 years. However, a randomized comparative trial is needed to provide final evidence compared to radiofrequency ablation.
AMERICAN JOURNAL OF GASTROENTEROLOGY
(2022)
Review
Oncology
Sarah Killcoyne, Rebecca C. Fitzgerald
Summary: Cancer cells evolve through DNA mutation, cell selection, and population expansion, driven by mutated driver genes and structural alterations to the genome. Early genomic instability in Barrett's esophagus (BE) may lead to esophageal adenocarcinoma (EAC). Understanding these patterns and genomic changes can improve early detection of EAC and provide insights into cancer evolution.
NATURE REVIEWS CANCER
(2021)
Review
Gastroenterology & Hepatology
Madhav Desai, Thomas Rosch, Suneha Sundaram, Viveksandeep Thoguluva Chandrasekar, Divyanshoo Kohli, Marco Spadaccini, Cesare Hassan, Alessandro Repici, Prateek Sharma
Summary: Despite initial high success rates, the efficacy of Barrett's endoscopic therapy (BET) declines over a period of 3.4 years according to a systematic review and meta-analysis. Only a few studies have reported follow-ups longer than 5 years, showing a possible correlation between longer follow-up periods and decreased BET efficacy. More high-quality controlled intervention trials are needed to assess the long-term durable remission rates of BET.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
(2021)
Review
Biology
Marco Spadaccini, Ludovico Alfarone, Viveksandeep Thoguluva Chandrasekar, Roberta Maselli, Antonio Capogreco, Gianluca Franchellucci, Davide Massimi, Alessandro Fugazza, Matteo Colombo, Silvia Carrara, Antonio Facciorusso, Pradeep Bhandari, Prateek Sharma, Cesare Hassan, Alessandro Repici
Summary: Over the last two decades, endoscopic eradication therapy has become the preferred treatment strategy for patients with Barrett's oesophagus-related dysplasia and early oesophageal adenocarcinoma. Radiofrequency ablation is the first-line option due to its proven effectiveness and safety, although it is expensive and not universally applicable. Cryotherapy techniques and hybrid argon plasma coagulation have shown promising results as potential alternatives to radiofrequency ablation. This review aims to provide a practical guide for the different ablative options for Barrett's oesophagus.
Article
Gastroenterology & Hepatology
Quinn S. Solfisburg, Sarmed S. Sami, Joel Gabre, Ali Soroush, Lovekirat Dhaliwal, Claire Beveridge, Zhezhen Jin, John M. Poneros, Gary W. Falk, Gregory G. Ginsberg, Kenneth K. Wang, Charles J. Lightdale, Prasad G. Iyer, Julian A. Abrams
Summary: Recurrence of intestinal metaplasia at the gastroesophageal junction (GEJIM) after endoscopic eradication of Barrett's esophagus (BE) is common, but not associated with an increased risk of subsequent dysplasia. Older age and longer initial BE length are independently associated with recurrence.
GASTROINTESTINAL ENDOSCOPY
(2021)
Article
Gastroenterology & Hepatology
Chetan Mittal, V. Raman Muthusamy, Violette C. Simon, Brian C. Brauer, Daniel K. Mullady, Thomas Hollander, Ian Sloan, Vladimir Kushnir, Dayna Early, Amit Rastogi, Hazem T. Hammad, Steven A. Edmundowicz, Samuel Han, Adarsh M. Thaker, Ezenwanyi Ezekwe, Sachin Wani, Mary J. Kwasny, Srinadh Komanduri
Summary: This study aimed to define the threshold of endoscopic eradication therapy (EET) sessions required to achieve complete eradication of intestinal metaplasia (CE-IM). The study found that in the majority of patients, three EET sessions can achieve CE-IM. Age and length of Barrett's esophagus were significant predictors of incomplete response.
Article
Multidisciplinary Sciences
Arvind J. Trindade, Jianying Zhang, Kara L. Raphael, Jiejing Qiu, John Hauschild, Petros C. Benias
Summary: This retrospective observational study examined the utilization of endoscopic ablation therapy and esophagectomy in patients with Barrett's esophagus. The study found an increasing trend in the utilization of ablation therapy, while esophagectomy showed a decreasing trend. These findings suggest that endoscopic ablation therapy has become the predominant method of treatment for Barrett's esophagus with dysplasia.
SCIENTIFIC REPORTS
(2022)